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Abstract
Rationale Whilst the FDA-approved anorectic, lorcaserin and
various 5-hydroxytryptamine (5-HT)6 receptor antagonists re-
duce feeding, a direct assessment of their impact upon feeding
behaviour is less clear. We therefore examined the action of
lorcaserin and the clinical-stage developmental candidate 5-
HT6 receptor antagonist, SB-742457, upon microstructural
analysis of licking behaviour. Such analysis provides a rich
source of information about the mechanisms controlling food
intake.
Objectives The objective of the present study was to gain
insight into the influence upon feeding behaviour of the 5-
HT2C receptor agonist, lorcaserin and the developmental 5-
HT6 receptor antagonist, SB-742457.
Methods The impact of lorcaserin and SB-742457 upon lick-
ing behaviour of non-deprived rats for a glucose solution was
assessed using microstructural analysis.
Results Lorcaserin (0.1–3.0 mg/kg) displayed a dose-
dependent ability to reduce glucose consumption via reduc-
tion in the number of bouts of licking. A similar action was
evident with SB-742457, but only at the lowest dose tested
(3.0 mg/kg).
Conclusions The behavioural actions of both lorcaserin and
SB-742457 demonstrate they directly promote satiety.
Keywords Lorcaserin . 5-HT2C receptor . 5-HT6 receptor .
Obesity . Feeding behaviour .Microstructural analysis
Introduction
Obesity is a major public health problem in many countries
and gives rise to various co-morbidities including type 2 dia-
betes, hypertension and dyslipidemia. These sequelae create a
considerable burden to the healthcare system (e.g. Ogden et al.
2014) and at least in the USA are second only to tobacco use
as a cause of death in under 70 year olds (Danaei et al. 2009).
Against this background, the requirement for safe and effica-
cious anti-obesity drugs is clear.
There is a considerable history of drugs targeting the 5-
hydroxytryptamine (5-HT) serotonin system influencing ap-
petite and feeding in pre-clinical models and patients (e.g.
Blundell 1977; Vickers and Dourish 2004). For instance,
drugs that increase 5-HT neurotransmission such as fenflur-
amine (and its d-enantiomer, dexfenfluramine) alone or in
combination with phentermine (Fen-Phen; e.g. Weintraub
et al. 1984), and subsequently, sibutramine (which also
increases synaptic levels of noradrenaline and dopamine;
McNeely and Goa 1998; Balcioglu and Wurtman 2000) pos-
sess clear therapeutic anorectic efficacy in patients (for review,
see Halford et al. 2011); however, their adverse effects on the
cardiovascular system (e.g. valvulopathy, pulmonary
hypertension; Fitzgerald et al. 2000; Rothman et al. 2000;
Launay et al. 2002) eventually led to their removal from the
market. Investigation concerning which 5-HT receptors medi-
ate the therapeutic actions of drugs like fenfluramine and
sibutramine suggested the 5-HT2C receptor as having at least
a major role (e.g. Jackson et al. 1997; Vickers et al. 1999;
Dutton and Barnes 2006; Higgs et al. 2011; Berglund et al.
2013). Fortunately, the activation of the 5-HT2C receptor does
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not appear to be associated with the adverse cardiovascular
effects allowing direct 5-HT2C receptor agonists to be evalu-
ated for the anorectic efficacy. However, there is a need to
avoid concomitant 5-HT2A or 5-HT2B receptor activation as
the former results in neuropsychiatric events (e.g.
hallucinations; Nichols 2004) and the latter receptor may
be responsible for some of the cardiovascular complications
arising from drugs like fenfluramine (Fitzgerald et al. 2000;
Rothman et a l . 2000; Launay et a l . 2002) . The
pharmacophores of the 5-HT2A, 5-HT2B and 5-HT2C receptors
are structurally similar (for reviews, see Meltzer and Roth
2013; Michino et al. 2015) and hence it has proved challeng-
ing to develop 5-HT2C receptor agonists with presumed suffi-
cient selectivity. One such proposed agent, however, is
lorcaserin, which displays around 100- and 19-fold selectivity
as an agonist for the human 5-HT2C receptor compared to the
human 5-HT2B receptor and human 5-HT2A receptor, respec-
tively (functional selectivity assessed by inositol phosphate
accumulation via the appropriate receptor; Smith et al. 2008;
Thomsen et al. 2008), although a lower selectivity is apparent
(12- and 7-fold, respectively) when the relative affinities are
compared (Thomsen et al. 2008; it should be noted that in
these studies, lorcaserin was a partial agonist at the human
recombinant 5-HT2A receptor with an intrinsic activity of
0.75). This discrepancy between the selectivity for the three
5-HT2 receptors when comparing agonist potency or receptor
affinity may indicate lorcaserin displays biased agonism and/
or there were differential levels of receptor reserve apparent
when using recombinant expression of the different 5-HT2
receptors. Nevertheless, lorcaserin is now approved by the
FDA as a prescription medication to assist weight loss regi-
mens (trade name, Belviq®; http://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm309993.htm), although
a caveat to the approval is the need to perform post-marketing
studies to, for example, better examine the risk of major ad-
verse cardiac events. However, despite this recent approval,
there are a relatively small number of papers in the literature
reporting the actions of lorcaserin in pre-clinical models of
obesity and feeding (Smith et al. 2008; Thomsen et al. 2008;
Fletcher et al. 2009; Higgins et al. 2014; Burke et al. 2014)
and these have only reported lorcaserin’s effect on the quantity
of food intake (acute lorcaserin administration) or on body
weight (chronic lorcaserin administration). Given the com-
plexity of 5-HT’s action upon feeding, in an attempt to gain
further insight into the action of lorcaserin upon feeding be-
haviour, in the present study, we report the microstructural
analysis of lorcaserin’s action upon licking behaviour of rats
to ingest a liquid diet. Analysis of licking responses provides a
rich source of information concerning the principal factors
(including satiety), which determine food intake (e.g. Davis
and Smith 1992; Davis et al. 2001). To establish the behav-
ioural mechanisms that underlie drug-induced changes in food
intake, the effects of pharmacological manipulations can be
compared with available reference standards that display dis-
tinctive effects on licking patterns associated with satiety or
orosensory variables (e.g. Davis and Smith 1992; Davis et al.
2001). We have previously used this approach successfully to
reveal the effects of diverse pharmacological agents on eating
with high resolution. For example, we have found that whilst
both the cannabinoid CB1 receptor antagonist, rimonabant
and the 5-HT mimetic, sibutramine, both decreased total in-
take of glucose, this was achieved by different mechanisms;
rimonabant primarily decreased licking bout duration (Higgs
et al. 2003) whereas sibutramine decreased bout number
(Higgs et al. 2011). Such data indicates that cannabinoid neu-
rotransmission is important for food palatability whereas 5-
HT neurotransmission influences satiety. Identification of
such mechanistic differentiation highlights the usefulness of
microstructural analysis of feeding behaviour to better under-
stand the mechanisms of drug-induced changes in food intake.
This present report is extended further to also assess in the
behavioural action of a selective 5-HT6 receptor antagonist,
SB-742457, using the microstructural analysis of licking be-
haviour. The 5-HT6 receptor has also been proposed as a suit-
able therapeutic target to reduce obesity although the peer-
reviewed reports simply assess the ability of 5-HT6 receptor
ligands to modify the quantity of food intake or body weight
(Woolley et al. 2001; Fisas et al. 2006; Garfield et al. 2014).
Materials and methods
Animals
For each compound tested, 12 drug naïve adult male hooded
Lister rats (Charles River, UK), weighing approximately
200 g at the beginning of training, were housed in groups of
four. Rats were maintained on a 12:12 h light/dark cycle
(lights on at 0700 hours), at a constant temperature of 21±
1 °C (humidity 50 %). Food pellets (rat and mouse expanded
ground maintenance diet; Special Diet services, Cambridge,
UK) and water were available ad libitum, except when the
animals were in the test chambers. All testing was conducted
in the light phase between 0900 and 1700 hours. The experi-
ments were carried out in accordance with the terms of the UK
Animals (Experimental Procedures) Act, 1986.
Drugs
The selective 5-HT2C receptor agonist, lorcaserin (custom
synthesis performed by Axon Medchem) was prepared for
injection by dissolving in 0.9 % saline and was administered
via the i.p. route. The selective 5-HT6 receptor antagonist, SB-
742457 (Axon Medchem), was homogenised in 1 % methyl-
cellulose and administered orally. Both drugs were adminis-
tered in a volume of 1.0 ml/kg.
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Apparatus
Testing was carried out using an MS80 multistation lick anal-
ysis system (Dilog Instruments, Tallahassee, FL, USA), which
has been described in detail previously (Higgs and Cooper
1997). Briefly, rats were placed in a Perspex chamber that
had an opening in the centre of the front wall allowing access
to a drinking spout that was connected to a plastic 50-ml
measuring tube containing the glucose solution (200 mM glu-
cose dissolved in distilled water 200 mM), which is palatable
to rats. The lickometer was connected to an amplifier that
passed less than 60 nA through the rat every time tongue
contact was made with the spout. The current was fed to a
standard personal computer (Opus Technology, Surrey, UK),
which stored the time of each tongue contact to the nearest
millisecond.
Training
A non-deprivation, free-feeding paradigm was used to avoid
the possibility that deprivation might modify licking re-
sponses that would complicate identification of independent
drug effects. During the training phase, each rat was placed in
the test chamber daily with access to the drinking spout to
obtain the glucose solution. The rats were left in the test ap-
paratus for 20min from the time of the first lick at the drinking
spout for the glucose solution. This trainingwas repeated daily
until each rat achieved a consistent number of total licks (typ-
ically achieved by day 5). Although 12 rats in each study
(lorcaserin or SB-742457) began training, 1 and 2 rats failed
to achieve baseline levels of licking in the lorcaserin and SB-
742457 studies, respectively; these rats were not studied
further.
To familiarise the rats with the drug administration proce-
dure, on the 2 days before drug testing began, each rat re-
ceived saline administration via the appropriate route of
administration.
Testing
Administration of vehicle or drug was made using a repeated-
measures design, with the order of treatment randomised.
After injection, each rat was returned to the home cage before
being placed individually in a test chamber, where it had ac-
cess to the glucose solution for 20 mins. The vehicle/drug
administration test interval for the lorcaserin study was 30
and 60 min for the SB-742457 study. ‘Wash-out’ between
successive administration of drug/vehicle was at least 48 h.
Analysis
The accumulated lick data were grouped into bouts defined as
the licking occurring with an upper inter-lick interval of less
than 400 ms, which corresponds to an interval that is just
above twice the average inter-lick interval and is consistent
with our previous studies (Higgs and Cooper 1996, 1997,
1998, 2000). Drug impact was examined on four microstruc-
tural variables: the number of bouts, the duration of a bout, the
intra-bout lick rate (defined as the average number of licks per
second within a bout) and the latency to begin licking (timed
from the shutter opening allowing access to the drinking spout
to the first lick). Analysis of data was by one-way analysis of
variance (ANOVA) for repeated measures. The effects of drug
relative to vehicle were assessed using a post hoc t test
corrected for multiple comparisons. For the number of bouts
of licking, values were obtained for each rat, and then mean
values and standard error of the mean (SEM) were calculated
for each treatment. For bout duration and intra-bout lick rate,
values across the test period for each rat were averaged, and
the mean and SEMwere subsequently calculated for treatment
groups. Three of the 11 rats in the lorcaserin study failed to
register a lick at the highest dose of lorcaserin tested
(3.0 mg/kg) and so could not contribute to the microstructural
analysis. The data were analysed both without the data from
these rats and using multiple imputation to substitute for the
missing values. The pattern of results was similar in both
cases. For brevity, we just report the results with the affected
data points excluded. The latency data were not normally dis-
tributed and so the data were square root transformed before
analysis. Statistical tests were performed using Sigma Stat
(Jandel Corporation, San Rafael, CA, USA, 1992–1994). A
result was considered statistically significant if p<0.05.
Results
Dose-dependent effect of lorcaserin on licking for glucose
solution
There was a main effect of lorcaserin on the amount of glucose
solution consumed ((4 ,28)=6, p<0.001). In comparison to
the vehicle response, there was a significant reduction in glu-
cose solution consumed after the 1.0 mg/kg (p<0.05) and
3.0 mg/kg doses of lorcaserin (p<0.01; Fig. 1).
Microstructural analysis
There was a main effect of lorcaserin on total licks for the
glucose solution (F (4, 28)=6; p<0.01; Table 1). In compar-
ison to the vehicle response, there was a significant reduction
in the total licks for the glucose solution after the 1.0 and
3.0 mg/kg doses of lorcaserin (p<0.05; Table 1); the
lorcaserin-induced reduction in total licks was due to a reduc-
tion in the number of lick bouts (F(4, 28)=5.7; p<0.001;
Table 1) rather than an effect on lick bout duration (F(4,
28)=1.9; p=0.1; Table 1). There was a main effect of
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lorcaserin on intra-bout lick rate (F(4, 28)=6; p<0.01) with a
significant reduction in intra-bout lick rate but only at the
highest dose tested of lorcaserin (3.0 mg/kg; p<0.01;
Table 1). There was also a significant effect of lorcaserin on
the latency to lick (F(4,28)=4.6, p<0.01); post hoc analysis
indicated that latency was significantly increased at the
highest does tested (3.0 mg/kg; Table 1).
Effect of SB-742457 on licking for glucose solution
There was a main effect of SB-742457 on the amount of
glucose solution consumed (F(3, 27)=3.4; p<0.05). In com-
parison to the vehicle response, there was a significant reduc-
tion in glucose solution consumed after the 3.0 mg/kg dose of
SB-742457 (p<0.05; Fig. 2).
Microstructural analysis
There was a significant reduction in total licks for glucose
solution after SB-742457 (F(3, 27)=3.3; p<0.05) but this
was only significant at the lowest dose tested (3.0 mg/kg;
p<0.01; Table 2). The reduction in total licks was due to a
decrease in the number of lick bouts (F(3, 27)=2.8; p<0.05;
Table 2) rather than bout duration (F(3, 27)=1.8; p=0.2;
Table 2). There was a significant main effect of SB-742457
on intra-bout lick rate (F(3, 27)=4.8; p<0.01) but the only
significant reduction was at the highest dose tested (30 mg/kg;
p<0.01; Table 2). There was no significant effect of
SB-742457 on latency to start licking (F(3, 27)=0.14,
p=0.9; Table 2).
Discussion
Previous studies exploring the anti-obesity actions of the 5-
HT2C receptor agonist, lorcaserin (Smith et al. 2008; Thomsen
et al. 2008; Higgins et al. 2014; Burke et al. 2014) or 5-HT6
receptor antagonists (Woolley et al. 2001; Garfield et al. 2014)
in animal models have utilised food intake or body weight to
measure their impact. The present study utilised microstruc-
tural analysis of licking behaviour in rats for a liquid diet to
offer direct insight into the behavioural mechanisms influ-
enced by lorcaserin and the selective 5-HT6 receptor antago-
nist, SB-742457. By examining the pattern of licking
*
**
Fig. 1 Dose-dependent ability of lorcaserin to reduce the consumption of
glucose. Data represent the mean±SEM, n=12, *p<0.05, **p<0.01
Table 1 Total number of licks and microstructural data after lorcaserin. The microstructural data are shown as means. Standard error difference
between means is shown in brackets
Microstructure analysis Vehicle Lorcaserin
0.1 mg/kg 0.3 mg/kg 1.0 mg/kg 3.0 mg/kg
Number of licks 2091.4 (192.4) 1366.3 (325.7) 1837.3 (231.0) 1087.4* (292.7) 635.3**(224.5)
Bout duration (s) 3.4 (0.4) 3.5 (0.5) 3.3 (0.4) 2.4 (0.4) 2.4 (0.4)
Bout number 98.0 (10.1) 60.5* (13.8) 89.5 (12.1) 59.5 (15.5)* 36.0**(11.4)
Intra-bout lick rate (licks/s) 6.3 (0.2) 6.2 (0. 2) 6.3 (0. 2) 6.6 (0.2) 5.8* (0.2)
Latency (s) 31.5 (17.9) 26.8 (11.2) 25.0 (8.6) 39.7 (18.2) 262.5** (130.1)
Asterisks indicate significantly different from vehicle control condition (*p<0.05; **p<0.01)
* 
Fig. 2 Ability of SB-742457 to reduce consumption of glucose. Data
represent the mean±SEM, n=12, *p<0.05
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behaviour predictions can be made concerning the influence
of drug upon satiety and the palatability of food (Davis and
Smith 1992; Breslin et al. 1996; Higgs and Cooper 1996,
1997, 1998; Davis et al. 2001; Cooper and Higgs 2005;
Higgs et al. 2011).
In the present study, lorcaserin treatment resulted in a se-
lective reduction in the number of bouts of licking behaviour
that was responsible for the reduced food intake. Importantly,
the effect on bout number was also observed at doses that had
no non-specific effects on licking latency or lick rate. Rats lick
at a constant rate of about 6–7 licks/s (Stellar and Hill 1952)
and drug-induced disruption of this rate would suggest that a
pharmacological treatment might be affecting sensorimotor
coordination, as distinct from a specific effect on the controls
of ingestion. For example, Davis and Smith (1992) showed
that intra-bout lick rate is affected by moving the drinking
spout progressively further away from an animal, but not by
altering the solution concentration. Hence, the current pattern
of results suggests that since lorcaserin was able to decrease
bout number in the absence of a reduced intra-lick rate, a
modulation of motoric activity did not complicate interpreta-
tion. However, it should be noted that the effect was not linear
in that the 0.3 mg/kg dose has less of an effect on bout number
than the 0.1 mg/kg dose. Similar effects on licking microstruc-
ture are observed when delaying negative feedback post-
ingestive signals, by adding the non-digestible sugar mannitol
to glucose solutions (Davis and Levine 1977). Conversely, the
addition of the non-nutritive sweetener saccharin to glucose,
which selectively increases palatability, increases bout dura-
tion whilst having minimal effects on bout number (Breslin
et al. 1996). Hence, selective action of lorcaserin on bout
number supports promotion of satiety by the drug rather than
an effect on taste palatability, which is consistent with the
mechanism of action of some less-selective 5-HT2C receptor
agonists in rodents (e.g. Ro 60–0175; Clifton et al. 2000) and
humans (Thomas et al. 2014) as well as the 5-HT releasing
agents, fenfluramine (d-fenfluramine) and sibutramine (Tallett
et al. 2009; Higgs et al. 2011; Burke et al. 2014).
One study that has examined the behavioural effects of
lorcaserin assessed its effect on the behavioural satiety se-
quence (Higgins et al. 2014). It was reported that lorcaserin
(0.3–1.0 mg/kg) advanced the behavioural satiety sequence in
non-deprived rats consuming a sweetened mash diet over 1 h,
consistent with the effect on satiety reported here. Lorcaserin
was also reported to reduce deprivation-induced food intake,
operant responding for food- and nicotine-motivated behav-
iours (Higgins et al. 2012). These data suggest that lorcaserin
has effects to reduce responding for both food and drug re-
wards. One explanation for the overall pattern of behavioural
responding after lorcaserin is that the drug has a dual mecha-
nism of action to modulate neuronal systems involved in both
(1) the processing of metabolic signals related to nutritional
state and (2) reward-related processing (Asin et al. 1992;
Higgins et al. 2012). Indeed, it may be that both these mech-
anisms are critical for the observed effects of lorcaserin on
food intake. The pleasantness of food is known to decline as
food is eaten, a phenomenon known as alliesthesia (Cabanac
1971). It is possible that lorcaserin enhances alliesthesia, such
that food becomes less rewarding at a faster rate during a meal,
thereby enhancing satiety. This suggestion requires further
testing, but such a unifying explanation of the anorectic effects
of lorcaserin is consistent with other evidence that points to-
wards important interactions between homeostatic and reward
processes in appetite control (Berthoud 2011).
In terms of the underlying neuronal mechanisms for
lorcaserin and SB-742457 to promote satiety, elegant neuro-
biological studies have demonstrated a common population of
pro-opiomelanocortin (POMC) neurones within the arcuate
nucleus of the hypothalamus that are activated by 5-HT2C
receptor agonists (Berglund et al. 2013; Burke et al. 2014)
and also d-fenfluramine and sibutramine to signal their ano-
rectic actions (Heisler et al. 2002, 2006; Lam et al. 2008; Xu
et al. 2008, 2010; Berglund et al. 2013; Burke et al. 2014); and
is consistent with their effects upon satiety (Hillebrand et al.
2002). Results from the Heisler laboratory have also implicat-
ed the paraventricular nucleus (PVN) within the
Table 2 Total number of licks and microstructural data after SB-742457. The microstructural data are shown as means. Standard error difference
between means is shown in brackets
Microstructure analysis Vehicle SB-742457
3.0 mg/kg 10 mg/kg 30 mg/kg
Number of licks 1456.7 (199.9) 992.8* (255.2) 1130.7 (249.9) 1238.9 (278.4)
Bout duration (s) 2.7 (0.5) 1.9 (0.1) 2.1 (0.3) 2.0 (0.3)
Bout number 97.2 (12.8) 73.5* (17.2) 80.1 (13.9) 114.5 (27.3)
Intra-bout lick rate
(licks/s)
6.4 (0.1) 6.4 (0.2) 6.3 (0.2) 5.9* (0.1)
Latency (s) 84.7 (46.9) 66.1 (28.0) 76.1 (20.7) 62.7 (23.9)
Asterisks indicate significantly different from vehicle control condition (*p<0.05)
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hypothalamus as a target for a hypophagic dose of the selec-
tive 5-HT6 receptor antagonist, SB-399855 (Garfield et al.
2014). Hence, the arcuate-PVN circuit would appear to be
important to mediate the hypophagic actions of both 5-HT2C
receptor agonists and 5-HT6 receptor antagonists; the latter
potentially increasing neuronal activity via disinhibition
(Garfield et al. 2014, 2015). 5-HT2C receptors are also located
on GABA neurons in the VTA and activation of these recep-
tors has been reported to decrease DA release in the nucleus
accumbens and frontal cortex (Di Matteo et al. 2002). This
latter mechanism may underlie the effects of lorcaserin on
reward-related responding.
Lorcaserin’s positive results from three phase III tri-
als (Smith et al. 2010; Fidler et al. 2011; O’Neil et al.
2012; for meta-analysis of the data, see Chan et al.
2013) in the relative absence of adverse side effects,
importantly including only a very small additional risk
of cardiovascular events (Weissman et al. 2013), led to
the FDA approving lorcaserin when combined with a
reduced calorie diet and exercise regimen for obese
(BMI ≥30) or overweight adults (BMI ≥27) who also
have at least one co-morbid condition (e.g. hyperten-
sion, type-2 diabetes, dyslipidemia). Despite approval
as a medication, there is still much to understand about
lorcaserin’s effects on eating behaviour processes; in
particular, its effects on reward processes and the rela-
tionship of such actions upon satiety. Knowledge of the
specific behavioural mechanisms will be helpful in guid-
ing advice and support for patients prescribed the drug,
for example in educating them about what to expect
from treatment.
Lorcaserin’s impact upon feeding behaviour of rats identi-
fied in the present study is consistent with the self-reporting of
decreased appetite and hunger of patients receiving the drug
(Martin et al. 2011), further supporting the use of microstruc-
tural analysis of licking behaviour in pre-clinical models to
predict clinical outcome.
Whilst an early report indicated that activation of the
5-HT6 receptor may offer therapeutic potential to pro-
mote weight loss (Fisas et al. 2006), evidence from the
use of various 5-HT6 receptor antagonists (Woolley
et al. 2001; Garfield et al. 2014; for review, see Heal
et al. 2008 that also includes a review of data presented
at conferences) and knock-down of 5-HT6 receptor gene
expression (Woolley et al. 2001) indicates inhibition of
5-HT6 receptor signalling possesses the clearest anorec-
tic potential from targeting this receptor. This effect
arising from a blockade of 5-HT’s actions contrasts the
dogma of 5-HT’s influence upon feeding. Similar to the
situation with lorcaserin, data arising from the use of 5-
HT6 receptor antagonists in feeding studies use quantity
of food intake (acute drug administration studies) or
body weight (chronic drug administration studies) as
the response readouts (Woolley et al. 2001; Garfield
et al. 2014; for review, see Heal et al. 2008), although
data presented at a conference indicates that the 5-HT6
receptor antagonist, PRX-07034 promotes satiety
(Gannon et al. 2006; reviewed in Heal et al. 2008). In
the present study, we assessed the action of the selective
5-HT6 receptor antagonist, SB-742457, using the micro-
structural analysis of licking behaviour paradigm. SB-
742457 was selected for study as it is already a clinical
candidate (for Alzheimer’s disease; e.g. Maher-Edwards
et al. 2011) and hence would allow relatively rapid
translation of the present pre-clinical study into clinical
trial. SB-742457 at a dose likely to antagonise central
5-HT6 receptors (Idris et al. 2010; Witten et al. 2012)
decreased the number of bouts of licking behaviour that
was responsible for the reduction in food intake, dem-
onstrating a drug-induced increase in satiety. This effect,
however, was only evident at the lowest dose tested,
indicating the presence of an inverted bell-shaped re-
sponse curve for this drug, which has been reported
when investigating the action of this drug on other
types of behaviour (de Bruin et al. 2013). Similar to
the data obtained with lorcaserin, an effect of SB-
742457 upon the number of bouts of licking was appar-
ent without an effect upon licking latency or lick rate,
excluding motoric effects from influencing the response
to drug.
In summary, in the present study the microstructural anal-
ysis of ingestive behaviour identified that both the relatively
selective 5-HT2C receptor agonist, lorcaserin and the 5-HT6
receptor antagonist, SB-742457, displayed an anorectic ac-
tion by primarily reducing the number of bouts of licking
behaviour, which indicates a direct promotion of satiety by
both drugs. A better understanding of the behavioural mech-
anism of action of anti-obesity drugs allows informed deci-
sions to select drug combinations in the search for more
efficacious anti-obesity therapies. In addition, for the
lorcaserin study, the reverse translation of supporting data
from the clinic further validates the predictive value of this
behavioural model.
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